|Bid||210.91 x 800|
|Ask||210.76 x 900|
|Day's range||202.79 - 211.22|
|52-week range||137.21 - 306.98|
|Beta (5Y monthly)||1.05|
|PE ratio (TTM)||72.13|
|Earnings date||26 Oct 2022 - 31 Oct 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||266.56|
Signs 15-year Strategic Collaboration and Exclusive License AgreementWALTHAM, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced it has entered into a strategic partnership and exclusive license agreement with DRS Daylight Solutions to expand the use of mid-infrared (mid-IR) technology in the bioprocessing market. Through this agreement, Repligen will assume responsibility for the c
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. David Gardner: Thirty separate times, about every 10 weeks on this podcast over six years, I picked five stocks.